Biomaterial Database

The effects of cholinomimetic drugs and atropine on ACTH release. 1976

G B Makara, and E Stark

Acetylcholine (1 and 50 mug), carbamylcholine (1 and 10 mug), and oxotremorine (10 mug) were infused into the 3rd ventricle of rats with deafferented medial basal hypothalamus (MBH); infusions failed to stimulate ACTH release as shown by the plasma corticosterone level. Implants of an atropine-fluorescein mixture (200-250 mug) inhibited the stress-induced rise of plasma corticosterone only when dye from the implant stained large portions of the median eminence and the basal hypothalamus. Atropine implants near the electrodes inhibited the rise in plasma corticosterone usually produced by electrical stimulation in the anterior hypothalamus. Atropine crystals or a 2% atropine sulphate solution placed on the median eminence blocked conduction of action potential in the hypothalamo neurohypophyseal and tubero-infundibular pathways. The evidence will be discussed for and against the participation of a cholinergic synapse (in the MBH) that activates ACTH release after stressful neural stimuli.

UI	MeSH Term	Description	Entries
D007030	Hypothalamo-Hypophyseal System	A collection of NEURONS, tracts of NERVE FIBERS, endocrine tissue, and blood vessels in the HYPOTHALAMUS and the PITUITARY GLAND. This hypothalamo-hypophyseal portal circulation provides the mechanism for hypothalamic neuroendocrine (HYPOTHALAMIC HORMONES) regulation of pituitary function and the release of various PITUITARY HORMONES into the systemic circulation to maintain HOMEOSTASIS.	Hypothalamic Hypophyseal System,Hypothalamo-Pituitary-Adrenal Axis,Hypophyseal Portal System,Hypothalamic-Pituitary Unit,Hypothalamic Hypophyseal Systems,Hypothalamic Pituitary Unit,Hypothalamo Hypophyseal System,Hypothalamo Pituitary Adrenal Axis,Portal System, Hypophyseal
D007031	Hypothalamus	Ventral part of the DIENCEPHALON extending from the region of the OPTIC CHIASM to the caudal border of the MAMMILLARY BODIES and forming the inferior and lateral walls of the THIRD VENTRICLE.	Lamina Terminalis,Preoptico-Hypothalamic Area,Area, Preoptico-Hypothalamic,Areas, Preoptico-Hypothalamic,Preoptico Hypothalamic Area,Preoptico-Hypothalamic Areas
D007032	Hypothalamus, Anterior	The front portion of the HYPOTHALAMUS separated into the preoptic region and the supraoptic region. The preoptic region is made up of the periventricular GRAY MATTER of the rostral portion of the THIRD VENTRICLE and contains the preoptic ventricular nucleus and the medial preoptic nucleus. The supraoptic region contains the PARAVENTRICULAR HYPOTHALAMIC NUCLEUS, the SUPRAOPTIC NUCLEUS, the ANTERIOR HYPOTHALAMIC NUCLEUS, and the SUPRACHIASMATIC NUCLEUS.	Hypothalamus, Supraoptic,Anterior Hypothalamic Commissure,Anterior Hypothalamic Decussation of Ganser,Anteroventral Periventricular Nucleus,Anterior Hypothalamic Commissures,Anterior Hypothalamus,Commissure, Anterior Hypothalamic,Commissures, Anterior Hypothalamic,Hypothalamic Commissure, Anterior,Hypothalamic Commissures, Anterior,Nucleus, Anteroventral Periventricular,Periventricular Nucleus, Anteroventral,Supraoptic Hypothalamus
D007276	Injections, Intraventricular	Injections into the cerebral ventricles.	Intraventricular Injections,Injection, Intraventricular,Intraventricular Injection
D008297	Male		Males
D008473	Median Eminence	Raised area at the infundibular region of the HYPOTHALAMUS at the floor of the BRAIN, ventral to the THIRD VENTRICLE and adjacent to the ARCUATE NUCLEUS OF HYPOTHALAMUS. It contains the terminals of hypothalamic neurons and the capillary network of hypophyseal portal system, thus serving as a neuroendocrine link between the brain and the PITUITARY GLAND.	Eminentia Mediana,Medial Eminence,Eminence, Medial,Eminence, Median,Eminences, Medial,Eminentia Medianas,Medial Eminences,Mediana, Eminentia,Medianas, Eminentia
D010095	Oxotremorine	A non-hydrolyzed muscarinic agonist used as a research tool.	Oxytremorine
D010277	Parasympathomimetics	Drugs that mimic the effects of parasympathetic nervous system activity. Included here are drugs that directly stimulate muscarinic receptors and drugs that potentiate cholinergic activity, usually by slowing the breakdown of acetylcholine (CHOLINESTERASE INHIBITORS). Drugs that stimulate both sympathetic and parasympathetic postganglionic neurons (GANGLIONIC STIMULANTS) are not included here.	Parasympathomimetic Agents,Parasympathomimetic Drugs,Parasympathomimetic Effect,Parasympathomimetic Effects,Agents, Parasympathomimetic,Drugs, Parasympathomimetic,Effect, Parasympathomimetic,Effects, Parasympathomimetic
D002217	Carbachol	A slowly hydrolyzed CHOLINERGIC AGONIST that acts at both MUSCARINIC RECEPTORS and NICOTINIC RECEPTORS.	Carbamylcholine,Carbacholine,Carbamann,Carbamoylcholine,Carbastat,Carbocholine,Carboptic,Doryl,Isopto Carbachol,Jestryl,Miostat,Carbachol, Isopto
D003345	Corticosterone	An adrenocortical steroid that has modest but significant activities as a mineralocorticoid and a glucocorticoid. (From Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1437)